Sensorion
Sensorion SA is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. Founded in 2009, the company is engaged in clinical-stage research, with key products including SENS-111, currently in phase II trials for acute unilateral vestibulopathy, and SENS-401, which is in phase I trials for sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-300 in pre-clinical development for inner ear toxicity treatment. The company also collaborates with Cochlear Limited to explore combination therapies for cochlear implant patients, aiming to enhance therapeutic outcomes. Sensorion's commitment to addressing inner ear health positions it as a significant player in the biopharmaceutical landscape.
Koubachi
Acquisition in 2014
Koubachi AG, founded in 2009 and headquartered in Zurich, Switzerland, specializes in interactive plant care solutions. The company offers Wi-Fi Plant Sensors that monitor soil moisture, temperature, and light intensity, providing users with notifications and tailored care advice for their plants. Koubachi's product lineup includes a mobile application for iPhone, which serves as a plant care assistant, and a web application that enables users to access and manage sensor data. The sensors not only assess environmental conditions but also determine plant vitality, helping users optimize care routines. As of July 2015, Koubachi AG is a subsidiary of Husqvarna AB, continuing its mission to enhance the way individuals interact with and care for their houseplants.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.